Human Metabolome Technologies, Inc.
6090・Standard Market・Services
Advanced R&D Support Business
Single business segment centered on contract metabolome analysis using the CE-MS method
| Period | Current | Previous | Change |
|---|---|---|---|
| Revenue (cumulative Q3) | ¥1,107 million | ¥1,266 million (same period of prior year) | ↓ |
| Operating profit (cumulative Q3) | ¥208 million | ¥353 million (same period of prior year) | ↓ |
| Ordinary profit (cumulative Q3) | ¥209 million | ¥342 million (same period of prior year) | ↓ |
| Quarterly net profit attributable to owners of parent (cumulative Q3) | ¥165 million | ¥304 million (same period of prior year) | ↓ |
| Gross profit (cumulative Q3) | ¥699 million | ¥847 million (same period of prior year) | ↓ |
| Total assets | ¥2,287 million | ¥2,374 million (end of prior fiscal year) | ↓ |
| Net assets | ¥1,884 million | ¥1,908 million (end of prior fiscal year) | ↓ |
| Equity ratio | 82.4% | 79.6% (end of prior fiscal year) | ↑ |
| Depreciation (cumulative Q3) | ¥83 million | ¥75 million (same period of prior year) | ↑ |
| Quarterly net profit per share | ¥29.35 | ¥51.53 (same period of prior year) | ↓ |
| Full-year revenue forecast | ¥1,420 million | ¥1,454 million (prior fiscal year actual) | ↓ |
| Full-year operating profit forecast | ¥210 million | ¥249 million (prior fiscal year actual) | ↓ |
Business Details
Provides contract analysis services in which measurement samples received from customers are subjected to metabolome analysis via the CE-MS method (capillary electrophoresis mass spectrometry), with results delivered as reports. Main customers are pharmaceutical companies, academia, food companies, and chemical companies, addressing a wide range of life science R&D needs including biomarker exploration, elucidation of mechanisms of action, functional materials development, and improvement of bio-manufacturing productivity. From the first quarter of FY2026 (ending June 2026), the previous two segments, the Advanced R&D Support Business and the Healthcare Solutions Business, were integrated into a single segment. In addition to the domestic market, the company also operates in the US and European markets through its US subsidiary, HMT-A.
Recent Overview
Both revenue and profit declined significantly; full-year earnings forecast revised downward
Revenue for the cumulative third quarter of FY2026 (ending June 2026) (July 2025 to March 2026) was ¥1,107 million (down 12.6% year on year), and operating profit was ¥208 million (down 41.1%), both deteriorating significantly. The main causes were a decline in large-scale projects in the domestic academic field (down ¥112 million year on year) and sluggish overseas revenue. Meanwhile, the Bio-manufacturing Support Service performed well after its launch, achieving its annual target of ¥100 million by the third quarter. The Functional Materials Development Support Service has large-scale clinical trial revenue scheduled for the fourth quarter. On May 13, 2026, the full-year earnings forecast was revised downward to revenue of ¥1,420 million (down 2.4% year on year) and operating profit of ¥210 million (down 15.8%).
Key Products
Growth Drivers
- Favorable order trends for the Bio-manufacturing Support Service (BMS): the annual target of ¥100 million was already achieved in the cumulative third quarter following its launch in July 2025
- Increasing demand for R&D related to bio-manufacturing against the backdrop of bioeconomy promotion policies (government target: a ¥100 trillion market by 2030)
- Expectations for a recovery in the second half due to scheduled large-scale clinical trial revenue in the Functional Materials Development Support Service in the fourth quarter
- Expanding demand for the Functional Materials Development Support Service driven by the spread of the Foods with Function Claims system
- Acquisition of large-scale Life Science Research Support Service projects in the pharmaceutical company field and revenue growth from BMS (up ¥24 million year on year)
- Productivity improvement and expanded analysis capacity through high-throughput technology development, robot introduction, and AI analysis
Risks
- Risk of decline in large-scale projects in the domestic academic field: caused a revenue decline of ¥112 million year on year in the cumulative third quarter, with results significantly affected by the timing of project orders
- Risk of continued sluggish overseas revenue: overseas revenue continues to trend weakly, with no clear prospect of recovery in the US and European markets
- Risk related to the timing of large-scale project orders: the structure in which large-scale clinical trial revenue for the Functional Materials Development Support Service is concentrated in the fourth quarter causes large fluctuations in results between quarters
- Risk to achieving the full-year earnings forecast: based on the progress rate for the cumulative third quarter (78.0% for revenue, 99.4% for operating profit), revenue of ¥313 million and operating profit of ¥2 million must be recorded in the fourth quarter, and achievement is premised on the reliable recording of revenue from large-scale projects
- Profit pressure from increased R&D expenses and personnel costs: personnel costs continue to rise due to wage increases, and elevated SG&A expenses are pressuring profit
- Increased capital expenditure and depreciation: depreciation increased by ¥8 million year on year due to the introduction of the latest measurement equipment, pushing up cost of sales
- Decrease in net assets due to share buybacks: ¥90 million in treasury stock was acquired in the cumulative third quarter, reducing net assets by ¥24 million compared to the end of the prior fiscal year
Last updated: September 22, 2025